The binding of PD-L1 expressed by cancer cells to programmed death receptor-1 (PD-1) in immune cells is thought to inhibit effector T lymphocyte function and limit immune system-mediated tumor cell destruction [8,9]. This evidence concerns the gene CD274 and neoplasm.